DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma ...Middle East

First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study SAN DIEGO, Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced...

Read More Details
Finally We wish PressBee provided you with enough information of ( DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma )

Also on site :

• Which Tiny “Purse” Dog Breed Are You, Based on Your Zodiac Sign
• 'Talladega Nights' Actor, 59, Debuts Shocking New Look at Cannes
• Ex-Wives of Legendary Rocker, 81, Run Into Each Other at London Event